Announcements Trials
Browse Landscape

Phase

Phase 4 4Phase NA 3Phase 2 3Phase 3 2Phase 2/3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER_GOV 2INDUSTRY 2UNKNOWN 1OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2

Conditions

Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk 1Neutropenia 1Febrile Neutropenia 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × pegylated granulocyte colony-stimulating factor × Clear all
NCT06254742 2025-08-07

A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Withdrawn
Classical hematology

Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk

NCT04466137 2022-02-09

Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy

Xiamen Amoytop Biotech Co., Ltd.

Phase 3 Completed
398 enrolled
Classical hematology

Neutropenia, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡